Single company EIS

Single company EIS deals are private offers for experienced investors. 

They give you an opportunity to invest directly in a particular company you consider commercially compelling and able to deliver attractive returns, with the benefit of EIS tax relief. Please remember, tax rules can change and benefits depend on circumstances.

So, unlike with EIS funds where the asset manager makes the investment decisions on your behalf, you are in control, you decide which company to back. Get it right, and the reward could be considerable. 

But one cannot expect to get it right each time. You are investing in early-stage companies – inevitably some will fail. To help mitigate this, it might be wise to diversify and spread your EIS investments each year over a number of single companies.

How could you access single company deals? 

Thousands of EIS-qualifying companies raise funds. The latest figures show 3,905 businesses raised over £1.8 billion under EIS in just one year (2018/19). 

We aim to offer a selection of quality EIS opportunities you often wouldn't be able to get elsewhere. Each has been carefully assessed, either by Wealth Club or by reputable and established counterparties. To help you make your own informed decisions, we provide you with insight and comment on each offer. This is free to Wealth Club members. 

  • Our choice

    Advanced Commerce EIS

    Co-invest with Haatch Ventures, backing founder of £80m Attraqt Group plc in new award-winning B2B SaaS platform helping e-commerce retailers convert browsers to buyers. Read more, download research report and apply online...

    Read more about Advanced Commerce EIS
    Type
    Single company
    Sector
    Technology
    Target return
    23x (IRR 87%)
    Funds raised / sought
    £994,000 / £1.5 million
    Minimum investment
    £20,800
    Deadline
    15 Oct 2021 for next allotment
  • Our choice

    Glyconics EIS

    Co-invest alongside Deepbridge Capital and sector specialists in MedTech that could make early diabetes screening faster and more accurate – saving healthcare providers £millions. Glyconics has developed a patented point-of-care device that uses Infrared Spectroscopy (IRS) to detect diabetes highly accurately, more quickly than conventional methods (10 seconds versus potentially several weeks) and up to 90% more cheaply. Read more, download research report and apply online...

    Read more about Glyconics EIS
    Type
    Single company
    Sector
    Healthcare & Technology
    Target return
    11x
    Funds raised / sought
    £1.4 million / £1.5 million
    Minimum investment
    £20,130
    Deadline
    8 Oct 2021 for final close